Drug Trial Radar · NCT05385783
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
Last checked: Nov 19, 2026Latest source record: Mar 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
57
Actual
Start
Aug 2, 2022
Primary completion
Oct 16, 2023
Study completion Jan 18, 2024
Sponsor
- Lead sponsor
- Cybin IRL LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Clinilabs Drug Development Corporation; Drug Safety Navigator
- First posted
- May 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
Conditions
- Major Depressive Disorder
Interventions
CYB003Drug
CYB003 is a synthetic psilocybin analog.
PsychotherapyBehavioral
Manualized psychotherapy (called EMBARK) performed by facilitators
PlaceboDrug
Placebo
Psychological SupportBehavioral
Manualized psychological support performed by facilitators
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (All Arms)Time frame: Day 1 thru End of Study Visit (which is: Day 56 Arms A & B; Day 28 Arms C & D; Day 35 Arms E)
- Resting 12 Lead ECG ventricular rate (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, & Day 23
- Resting 12 Lead ECG ventricular rate (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
- Resting 12 Lead ECG ventricular rate (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
- Resting 12 Lead ECG PR interval (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
- Resting 12 Lead ECG PR interval (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
- Resting 12 Lead ECG PR interval (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
- Resting 12 Lead ECG QRS duration (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
- Resting 12 Lead ECG QRS duration (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
- Resting 12 Lead ECG QRS duration (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
- Resting 12 Lead ECG QT interval (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
- Resting 12 Lead ECG QT interval (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
- Resting 12 Lead ECG QT interval (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
- Resting 12 Lead ECG QTcF (Arms A & B)Time frame: Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23
- Resting 12 Lead ECG QTcF (Arms C & D)Time frame: Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9
- Resting 12 Lead ECG QTcF (Arms E)Time frame: Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16
- Holter monitoring (Arms A & B)Time frame: Day -1, Day 1, Day 22
- Holter monitoring (Arms C & D)Time frame: Day -1, Day 1, Day 8
- Holter monitoring (Arm E)Time frame: Day -1, Day 1, Day 8, Day 15
- Columbia Suicide Severity Rating Scale (CSSRS) Lifetime version (All Arms)Time frame: Screening
- Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms A & B)Time frame: Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 38, Day 42, and Day 56
- Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms C & D)Time frame: Day -1, Day 2, Day 7, Day 9, Day 15, Day 21, Day 28
- Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arm E)Time frame: Day -1, Day 2, Day 7, Day 9, Day 14, Day 16, Day 21, Day 28, Day 35
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
CenExel ACMR
Atlanta, Georgia
iResearch Atlanta
Decatur, Georgia
Clinilabs Drug Development Corporation
Eatontown, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.